Predicta Biosciences provides molecular diagnostics and immunotherapeutic discovery services for hematological diseases.
Predicta Biosciences has raised $23.4M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
Predicta Biosciences's investors include Engine Ventures, Illumina Ventures, Mass General Brigham Ventures, BrightEdge - American Cancer Society, Binney Street Capital.
Predicta Biosciences is headquartered in Boston, United States.
Predicta Biosciences provides molecular diagnostics and immunotherapeutic discovery services for hematological diseases.
Predicta Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Predicta Biosciences — Funding & Investors." VCBacked, October 1, 2025, https://www.vcbacked.co/company/predicta-biosciences. Accessed August 14, 2026.
VCBacked. (2025). Predicta Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/predicta-biosciences
{{cite web |title=Predicta Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/predicta-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated